Interpace Biosciences, Inc. (NASDAQ:IDXG) was the target of a significant decline in short interest in September. As of September 30th, there was short interest totalling 249,200 shares, a decline of 21.9% from the September 15th total of 319,000 shares. Currently, 6.2% of the company’s stock are short sold. Based on an average trading volume of 320,800 shares, the days-to-cover ratio is presently 0.8 days.
A hedge fund recently bought a new stake in Interpace Biosciences stock. Virtu Financial LLC bought a new position in Interpace Biosciences, Inc. (NASDAQ:IDXG) in the 2nd quarter, according to the company in its most recent disclosure with the SEC. The institutional investor bought 11,868 shares of the business services provider’s stock, valued at approximately $55,000. Virtu Financial LLC owned 0.29% of Interpace Biosciences as of its most recent filing with the SEC. 13.63% of the stock is currently owned by institutional investors.
Interpace Biosciences stock traded down $0.33 during mid-day trading on Friday, hitting $4.01. The stock had a trading volume of 533,048 shares, compared to its average volume of 457,902. The firm has a market capitalization of $16.19 million, a P/E ratio of -0.47 and a beta of 1.51. The company has a current ratio of 1.79, a quick ratio of 1.79 and a debt-to-equity ratio of 0.18. The firm’s 50 day moving average is $3.19 and its 200 day moving average is $4.71. Interpace Biosciences has a one year low of $2.57 and a one year high of $11.00.
IDXG has been the topic of a number of recent analyst reports. ValuEngine cut shares of Interpace Biosciences from a “strong-buy” rating to a “buy” rating in a report on Monday, August 3rd. HC Wainwright restated a “buy” rating and set a $11.00 target price (down previously from $12.00) on shares of Interpace Biosciences in a research note on Friday, June 26th. Finally, Zacks Investment Research lowered shares of Interpace Biosciences from a “hold” rating to a “sell” rating in a research note on Tuesday, September 29th. One equities research analyst has rated the stock with a sell rating and five have assigned a buy rating to the stock. The company has a consensus rating of “Buy” and a consensus target price of $10.75.
About Interpace Biosciences
Interpace Biosciences, Inc provides molecular diagnostic tests, bioinformatics, and pathology services for evaluating cancer risk in the United States. The company offers PancraGEN, a pancreatic cyst and pancreaticobiliary solid lesion genomic test that helps physicians better assess risk of pancreaticobiliary cancers using its PathFinderTG platform; and ThyGeNEXT, an oncogenic mutation panel to identify malignant thyroid nodules.
Recommended Story: What is Compound Annual Growth Rate (CAGR)?
Receive News & Ratings for Interpace Biosciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Interpace Biosciences and related companies with MarketBeat.com's FREE daily email newsletter.